Maintenance Therapy in NSCLC: Bevacizumab, Pemetrexed, or Both? (ECOG-ACRIN 5508)
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On July 30, 2019, Suresh S. Ramalingam and colleagues published the results of the ECOG-ACRIN 5508 Phase 3 clinical trial in the Journal of Clinical Oncology. This study compared the efficacy and safety of single-agent Bevacizumab (Avastin), single-agent Pemetrexed (Alimta), and their combination as maintenance therapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Study Design: ECOG-ACRIN 5508 Trial
The trial randomized patients with untreated non-squamous NSCLC who had not progressed after induction therapy with Carboplatin, Paclitaxel, and Bevacizumab into three maintenance groups:
- Bevacizumab Monotherapy
- Pemetrexed Monotherapy
- Bevacizumab + Pemetrexed Combination
The primary endpoint was overall survival (OS).
Key Survival Results (Median Follow-up 50.6 Months)
Overall Survival (OS)
- Bevacizumab Group: 15.9 months
- Pemetrexed Group: 14.4 months
- Combination Group: 16.4 months
- There were no statistically significant differences in OS between the three arms.
Progression-Free Survival (PFS)
- Bevacizumab Group: 4.2 months
- Pemetrexed Group: 5.1 months
- Combination Group: 7.5 months
- The combination group showed a longer PFS, but this did not translate into a significant OS benefit.
Safety and Toxicity
The incidence of Grade 4 adverse events was highest in the combination group (51%), compared to 30% in the Bevacizumab group and 38% in the Pemetrexed group.
- Pemetrexed-related toxicities: Anemia, fatigue, and neutropenia.
- Bevacizumab-related toxicities: Hypertension and proteinuria.
Conclusion
Dr. Suresh S. Ramalingam concluded that both Bevacizumab and Pemetrexed are effective as single-agent maintenance therapies for non-squamous NSCLC. Given the increased toxicity and lack of overall survival benefit with the combination, single-agent maintenance is generally recommended.
Source: Journal of Clinical Oncology - ECOG-ACRIN 5508 Results
#LungCancer #NSCLC #Bevacizumab #Avastin #Pemetrexed #Alimta #MaintenanceTherapy
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5